Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study

Area of Science:

• Neurology
• Cardiovascular Science
• Pharmacology

Background:

• Parkinson's disease (PD) treatment with levodopa (l-dopa) is associated with elevated serum homocysteine.
• Elevated homocysteine is a potential risk factor for endothelial dysfunction.

Purpose of the Study:

• To investigate the association between levodopa treatment, homocysteine levels, and endothelial function in Parkinson's disease patients.
• To compare endothelial function (flow-mediated dilation) across different PD treatment groups and controls.

Main Methods:

• Cross-sectional study comparing flow-mediated dilation (FMD) in four groups: PD patients on l-dopa, PD patients on l-dopa/entacapone, untreated PD patients, and healthy controls.
• Serum homocysteine levels were measured and correlated with FMD.

Main Results:

• PD patients on l-dopa exhibited significantly lower FMD compared to those on l-dopa/entacapone, untreated PD patients, and controls.
• Higher homocysteine levels were observed in PD patients treated with l-dopa.
• Elevated homocysteine was an independent predictor of reduced flow-mediated dilation.

Conclusions:

• Chronic levodopa treatment in Parkinson's disease may be linked to endothelial dysfunction.
• Increased homocysteine levels during levodopa therapy could contribute to endothelial impairment in PD patients.